Specific Aim 1. Recombination (DNA shuffling) and screening of variants identified from a scanning saturation library of [***] - [***] Sponsor: Aeglea PI: Xxxxxx Xxxxxxxx SRA Amendment No. 3 The University of Texas at Austin Page 4 of 5 Agreement No. UTA13-001113 ***Confidential Treatment Requested. Tertiary screening for expression, kinetics and stability (purified protein) • Biophysical studies of selected variants • [***] • PD study in mice to evaluate Cystine & Cysteine levels following single dose administration

Specific Aim 1. To determine whether a culturally tailored lifestyle intervention program based on healthy eating and moderate physical activity results in higher compliance with Institute of Medicine guidelines for GWG compared to women receiving standard care.

Specific Aim 1. To evaluate the relationship between HIV-positive pregnant women in Zambia and the role and influence that their Christian faith has on HAART adherence. The first phase of this grant incorporates a mixed method research study that gathers data to understand the impact that religion has on HIV-positive pregnant women and their decisions to adhere to HAART. Over an 11-month period, key informant interviews and surveys with 100 Christian leaders and 508 HIV-positive pregnant women will take place.

Specific Aim 1. To compare the subcellular localization of mGluR4, mGluR7 and mGluR8 in the rodent striatum. Tissue from normal mouse striatum was immunostained for mGluR4a, 7 or 8. Quantitative assessments of the relative abundance of labeled pre-and post- synaptic elements were made. The chemical phenotype of pre-synaptic terminals was determined using double immunoperoxidase methods for vGluT1 and vGluT2. The degree of colocalization of different group III mGluR types in individual terminals was quantified.

Specific Aim 1. To understand the rate and type of CAM use and non-use among chronically ill cancer patients receiving palliative care. The study of CAM in relation to palliative care has not been extensively researched, so it is an area that needs to start gaining attention in order for researchers to begin to consider the potential benefits it could have on the QOL of dying cancer patients. It is important to understand what types of CAM these patients are seeking, as well as the reasons for use. Understanding the rate and type of CAM use among this population will provide valuable information to the field as it continues to evolve. The findings of the proposed study may also be useful for chronically ill cancer patients in the future who may consider CAM. By gaining overall knowledge of what type of CAM this population is using and how often, it will provide valuable data on what types of CAM therapies or products may or may not be beneficial to them.

Related to Specific Aim 1

Country-Specific Provisions The Award shall be subject to any special provisions set forth in Exhibit A for your country, if any. If you relocate to one of the countries included in Exhibit A during the life of the Award or while holding Shares acquired upon vesting of the Restricted Share Units, the special provisions for such country shall apply to you, to the extent the Company determines that the application of such provisions is necessary or advisable in order to comply with applicable laws with regard to the acquisition, issuance or sale of the Shares or facilitate the administration of the Plan. Exhibit A constitutes part of this Agreement.
Product Support a. In the event that any goods delivered under this contract become defective or malfunction for any reason and at any time (even after the applicable warranty period has expired), including while “in-orbit” if integrated into a satellite, Seller shall promptly perform a failure verification or analysis and determine the appropriate corrective action at no additional cost to Buyer. Seller shall take the appropriate measures to correct all defects, determined to be Seller's responsibility, in all applicable documentation, undelivered goods, and delivered un-launched goods, as required by Buyer.
Product Supply The Parties shall reasonably cooperate and assist each other in transferring ownership of Product drug product and/or Product drug substance (such material, CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. collectively, the “Product Lots”) set forth in Exhibit A attached hereto as promptly as reasonably practicable following the Effective Date; provided, however, that neither Party shall be required to pay money to any Third Party, commence any litigation with, or offer or grant any accommodation (financial or otherwise) to any Third Party. Such Product Lots shall be delivered EXW (Ex Works) (Incoterms 2010) AMGEN, Thousand Oaks, California. Any expense for shipment shall be borne by AKERO (including any import or export duties or taxes). Subject to the terms of this Section 5.4 and Section 6.2 (Additional AMGEN Warranties), AMGEN transfers the Product Lots to AKERO “as is”, and makes no other representation to AKERO in connection therewith. The Parties have entered into a Quality Agreement substantially in the form attached hereto as Exhibit F, dated as of the date hereof, governing the quality of the Product Lots to be supplied pursuant to this Section 5.4. For the avoidance of doubt, Product Lots consisting of drug product as set forth in Exhibit A supplied pursuant to this Section 5.4 shall be labeled for their intended clinical use as set forth in Exhibit A and the labeling of any Product drug product manufactured after the Effective Date shall be the responsibility of AKERO. Except for the Licensed Materials and such Product Lots to be transferred to AKERO, AKERO shall be responsible for, and shall bear the cost of, obtaining (whether by manufacturing or causing to be manufactured) research, clinical and commercial supplies of the Product. From and after the Effective Date, AKERO shall be responsible for all costs and expenses in connection with the storage of, and any stability studies performed on, the Product Lots.
Specific Terms Whenever used in this Agreement, the following words and phrases, unless the context otherwise requires, shall have the following meanings:
Technical Specifications The Technical Specifications furnished on the CD are intended to establish the standards for quality, performance and technical requirements for all labor, workmanship, material, methods and equipment necessary to complete the Work. When specifications and drawings are provided or referenced by the County, these are to be considered part of the Scope of Work, and to be specifically documented in the Detailed Scope of Work. For convenience, the County supplied specifications, if any, and the Technical Specifications furnished on the CD.
State Specific Provisions N/A. ATTACHED EXHIBIT. The Exhibit noted below, if marked with an "X" in the space provided, is attached to this Note: X Exhibit A Modifications to Multifamily Note
Product Description The lead products covered by this Settlement Agreement is limited to following Amazon Identification Number (ASIN) B0BBMRLNV9, with the description, "Lesnow 63-37 Tin Lead Rosin Core Solder Wire for Electrical Soldering 0.8mm Soldering Wire Electronics Solder Content Solder Flux 1.8% (0.8mm, 50g)," which was offered for sale by the Settling Entity on xxxxxx.xxx, hereinafter the “Product” or “Products.”
Quality Specifications SANMINA-SCI shall comply with the quality specifications set forth in its Quality Manual, incorporated by reference herein, a copy of which is available from SANMINA-SCI upon request.
Contract Schedule The information set forth in the Contract Schedule is true and correct.

Specific Aim 1 Sample Clauses

Filter & Search

Related Clauses

Parent Clauses

Related to Specific Aim 1